semaj83/ctmatch_classification huggingface dataset:
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  COVID-19 Adult SARI patients with 2019-ncov infection confirmed by PCR; Absolute value of lymphocytes < 0. 6x 109/L; Severe respiratory failure within 48 hours and requires admission to ICU. (severe respiratory failure was defined as PaO2/FiO2 < 200 mmHg and was supported by positive pressure mechanical ventilation (including non-invasive and invasive mechanical ventilation, PEEP>=5cmH2O))  Age < 18 Pregnant Allergic to experimental drugs and patients have the following conditions: 1. Hypercholesterolemia 2. Hypertriglyceridemia 3. Liver disease 4. Renal disease 5. Sjögren syndrome 6. Pregnancy 7. Lactation 8. Depressive disorder 9. Body mass index less than 18 points or higher than 25 points 10. Contraindications for hormonal contraception or intrauterine device. 11. Autoimmune diseases A history of organ, bone marrow or hematopoietic stem cell transplantation 12. Patients receiving anti-hcv treatment 13. Permanent blindness in one eye 14. History of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery 15. The competent physician considered it inappropriate to participate in the study 16. HIV infection or other immunodeficiency or with an absolute neutrophil count ≤1.0 × 109/L 17. Abnormal liver biochemistry (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase) >1.5 × upper limit of normal or total bilirubin > upper limit of normal (unless Gilbert's disease with normal conjugated bilirubin) 18. Any of the following laboratory abnormalities are present at baseline Platelet count <150×109/L Serum albumin ≤ 3.5 g/dL INR ≥1.2 CPK ≥ ULN. 19. Significant liver fibrosis as evidenced by Fibrosis-4 (FIB-4) score >3.25 20. History of hypersensitivity to retinoic acid or any of its excipients or the class of neutrophil elastase inhibitors Known hypersensitivity to medications used in the study procedures (e.g. midazolam, fentanyl, and lidocaine for bronchoscopy)
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COVID Corona Virus Infection COVID19 The patient or legally authorized representative (LAR) must have the ability to understand and the willingness to provide a signed and dated informed consent form. 2. Age 18 years and over 3. The patient agrees to use adequate contraception for the duration of the treatment protocol and for 6 months post treatment. 4. Positive RT PCR testing for COVID-19 nucleic acid using nasopharyngeal swabbing or any other site 5. Patient meets ARDS as defined by Berlin and is on mechanical ventilation a. Berlin for ARDS are: i. bilateral opacities on chest imaging consistent with pulmonary edema ii. A need for positive pressure ventilation via endotracheal or tracheostomy tube iii. PaO2/FiO2 ratio ≤ 300mmHg with a minimum of 5 cmH20 PEEP iv. Infiltrates not fully explained by cardiac failure or fluid overload in the physician's best clinical judgement ARDS onset is considered the time that the last of 1-4 is met. Infiltrates considered "consistent with pulmonary edema" any infiltrate not due to mass, atelectasis, or effusion, or opacities known to be chronic (greater than 1 week old). Vascular redistribution or indistinct vessels or heart border alone do not qualify as opacities  Evidence of multiorgan failure involving one or more organs, excluding the lungs as defined below: 1. Presence of shock, defined as MAP < 65 mmHg with signs of peripheral hypoperfusion, or continuous infusion of 2 or more vasopressor or inotrope agents to maintain MAP ≥ 65 mmHg. 2. Serum bilirubin > 10 mg/dl 3. Platelet count < 50,000/ml 2. Evidence of acquired or congenital immunodeficiency (due to immunosuppressive therapy, HIV, previous treatment for cancer, etc.) 3. History of metastatic cancer in the past 3 years 4. History of previous treatments with MSCs or other cell therapies 5. Patient is co-enrolled in any other IND-sponsored clinical trials for COVID-19 6. Evidence of pregnancy or lactation 7. Moribund patient not expected to survive > 24 hours 8. Unable/unwilling to deliver lung protective ventilation 9. Patient is receiving Extracorporeal Membrane Oxygenation (ECMO)
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sars-CoV2 pregnant woman diagnosed with Sars Cov-2 during pregnancy singleton or twin pregnancy informed consent  virological or serological samples not done the day of delivery
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Covid-19 Anosmia Consecutive adult patients consulting the CAREB or hospitalized at the Nîmes teaching hospital due to COVID-19 infection (fever, persistent cough, tiredness, shortness of breath, diarrhea, abdominal pain, chest pain, sore throat, loss of smell or taste) COVID-19 confirmed by RT-PCR and / or chest CT or clinical characteristics (i.e an epidemic history and 2 clinical manifestations or at least 3 clinical manifestations) The patient must have given their free and informed consent and signed the consent form The patient must be a member or beneficiary of a health insurance plan "with anosmia" group scoring < 30 on a VAS 0-100 for olfactory ability Responding "yes" to question "have you lost your sense of smell in the last few days?" Negative result to olfactory test with n-Butanol diluted to 1/1000. "without anosmia" group scoring < 80 on a VAS 0-100 for olfactory ability Responding "no" to question "have you lost your sense of smell in the last few days?" Positive result to olfactory test with n-Butanol diluted to 1/16000  Patient suffering from serious medical problems or hospitalized in an intensive care unit for invasive ventilation or severe dyspnea Patient with neurological (motor, sensitive or cognitive), neuropsychiatric or vascular disorders Patient with a contraindication to MRI (pace maker, claustrophobic patient, metallic heart valve, etc.) Patient with a history of rhinological pathology or a sense of smell problem Patient with known neurological, psychiatric or neuroradiological manifestation.The subject is participating in a category 1 interventional study, or is in a period of determined by a previous study The subject is unable to express consent It is impossible to give the subject informed information The patient is under safeguard of justice or state guardianship Patient is pregnant, parturient or breastfeeding
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Enterococcal Bacteremia Hospitalized patient ≥1 positive blood culture with Enterococcus spp. (VRE or VSE) during hospitalization bacterial isolate(s) is/are available for further characterization Repeat blood culture(s) within 7 days from the first positive culture  Cultures obtained from patients not admitted to the hospital Isolate(s) not available for further studies
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Postoperative Nausea Postoperative Vomiting All patients who underwent medium to large surgery  Patients who are unable to communicate (orotracheal intubation after the surgery, confusion or agitation) or understand the Portuguese language Insulin dependent patients Pacients who had an increased QT interval on the electrocardiogram History of allergy to dexametasone, ondansetron or droperidol
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COVID 19 Patients above the age of 18 years old. 2. Patients with a diagnosis of COVID-19 on mechanical ventilation. 3. Patient maximum baseline temperature (within previous 12 hours) < 38.3°C. 4. Patients must have a surrogate or legally authorized representative able to understand and critically review the informed consent form  Patients without surrogate or legally authorized representative able to provide informed consent. 2. Patients with contraindication to core warming using an esophageal core warming device. 3. Patients known to be pregnant. 4. Patients with <40 kg of body mass. 5. Patients with DNR status. 6. Patients with acute stroke, post-cardiac arrest, or multiple sclerosis. 7. Patients with history of esophageal disease 8. Patients with a baseline epinephrine dose greater than 0.6 mcg/kg/min 9. Patients with atrial fibrillation, atrial flutter, or other multifocal atrial tachycardia with a heart rate greater than 110 beats per minute. 10. Patients on 0.2 mcg/kg/min or more of norepinephrine
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Cancer Female gender Age between 18 years old Patients known case of breast cancer Hemoglobin level is at least 8 g / dl Hematocrit level at least 30% The level of TSH is normal  Patients known case of heart disease with unstable conditions Disabling Pulmonary Disease and History of Asthma Patients known case of severe kidney disease (Creatinine level is greater than 2mg / dl Proteinuria) The SGOT level is more than 3 times of the normal threshold Bilirubin levels is greater than 2mg / dl Positive history of hypersensitivity to saffron, Rose water and Honey Uncontrolled pain severe infection serious illness Positive history of gout or high level of uric acid
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Stillbirth Infant, Low Birth Weight Infant, Very Low Birth Weight Sleep-Disordered Breathing Infant, Small for Gestational Age Fetal Hypoxia Pregnancy Complications Fetal Growth Retardation ≥18 years old low-risk singleton pregnancy in the last trimester of pregnancy (at least 28 weeks + 0 days but not more than 36 weeks + 0 days of gestation) access to and ability to use iPhone (for downloading and using Ajuvia app) residing in the Greater Adelaide Area  musculoskeletal disorder that prevents sleeping supine or on a certain side (e.g., arthritic shoulder) non-English speaking and reading
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Liver Cirrhosis Acute Kidney Injury Patients who are above 18 years of age Patients with Cirrhosis and SBP (community acquired /Health care associated/ nosocomial) with baseline Creatinine <1mg/dl, Bilirubin <4mg/dl  Antibiotic treatment within one week before the diagnosis of SBP (except for prophylactic treatment with norfloxacin) Significant cardiac failure, pulmonary disease Known Chronic Kidney Disease or findings suggestive of organic nephropathy (proteinuria, haematuria, or abnormal findings on renal USG) Hepatocellular carcinoma HIV infection GI bleed within 1 month before the study Ileus Grade 3 to 4 hepatic encephalopathy Other types of infection Shock
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bladder Pain Syndrome Interstitial Cystitis Men and women with non-Hunner and Hunner lesion disease Meeting AUA definition of BPS: An unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder associated with lower urinary tract symptoms of greater than 6 weeks duration in the absence of infection or other identifiable cause Stable treatment for 1 month day maximum of pain scores at least 4/10 on the numerical rating scale of pain in the bladder/pelvic area. Urinary frequency 8 or higher while awake. Nocturia 2 or higher. BPIC-SS 19 Agreement to not take opioids through the duration of the trial  Substance Use Disorder Diagnosis including Opioid Use Disorder Diagnosis Known allergy to naltrexone or naloxone Participation in another clinical trial Current or planned pregnancy, or breastfeeding Chronic pain in another location of the body that is more severe than that related to BPS Any intravesical instillation in last 8 weeks If on Elmiron, stable dose for last 3 months If on amitriptyline, stable dose for last 3 months Any botox within last 6 months Treatment for Hunners in the last 6 months
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  COVID19 Coronavirus Infection Pregnancy Disease Severe Acute Respiratory Syndrome Pregnant or puerperal women Diagnosis of flu syndrome on admission Testing for COVID-19 performed  Clinical impossibility of signing the Informed Consent Form (ICF), either by the patient or guardian (in the prospective arm) Incomplete or not located medical records (retrospective arm)
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  covid19 Infection Pregnancy Complications Neonatal Complications Any woman with : either proven COVID-19 infection= positive PCR test, OR probable COVID-19 infection = typical clinical symptoms AND typical pulmonary radiology during pregnancy or within 42 days postpartum whether or not this diagnosis is followed by hospitalization  Refusal to participate Major protected (curator, trusteeship)
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  COVID-19 2019 Novel Coronavirus Infection COVID-19 Infection COVID-19 infection 50 years for Groups A and B and 18-60 years for Groups C and D Female for groups A and B. Both male and female for groups C and D  Participants who have previously been part of a SARS-CoV-2 vaccine trial Current hospital admission due to another respiratory disease, such as influenza Obvious clinical deterioration due to another medical problem such as cardiovascular disease, diabetes or malignancy Evidence of HIV infection and/or participants on anti-retroviral drug therapy Participants on chemotherapy, biologics, immune-modulators or immunosuppressive drugs (not including intramuscular steroids for fetal lung maturity)